MA50120A - Méthodes de traitement à l'aide d'un promédicament d'amphétamine - Google Patents
Méthodes de traitement à l'aide d'un promédicament d'amphétamineInfo
- Publication number
- MA50120A MA50120A MA050120A MA50120A MA50120A MA 50120 A MA50120 A MA 50120A MA 050120 A MA050120 A MA 050120A MA 50120 A MA50120 A MA 50120A MA 50120 A MA50120 A MA 50120A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- methods
- medicinal product
- amphetamine pre
- amphetamine
- Prior art date
Links
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 title 1
- 229940025084 amphetamine Drugs 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762483779P | 2017-04-10 | 2017-04-10 | |
| US201762483790P | 2017-04-10 | 2017-04-10 | |
| US201762513131P | 2017-05-31 | 2017-05-31 | |
| US201762513107P | 2017-05-31 | 2017-05-31 | |
| US201762513016P | 2017-05-31 | 2017-05-31 | |
| US201762513034P | 2017-05-31 | 2017-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50120A true MA50120A (fr) | 2020-03-11 |
Family
ID=63793488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050120A MA50120A (fr) | 2017-04-10 | 2018-04-10 | Méthodes de traitement à l'aide d'un promédicament d'amphétamine |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200155687A1 (fr) |
| EP (1) | EP3618877A4 (fr) |
| JP (1) | JP2020516694A (fr) |
| CN (1) | CN111107878A (fr) |
| CA (1) | CA3059781A1 (fr) |
| MA (1) | MA50120A (fr) |
| WO (1) | WO2018191311A1 (fr) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070099999A1 (en) * | 2000-11-01 | 2007-05-03 | Epstein Mel H | Methods of treating depression |
| BR0311503A (pt) * | 2002-06-20 | 2005-02-22 | Lundbeck & Co As H | Uso de um composto, uso de um agonista parcial, agonista inverso, ou antagonista de receptor de gabab, composição farmacêutica, método para a identificação de compostos úteis para o tratamento de doenças, e, composto |
| CN101193650A (zh) * | 2005-04-08 | 2008-06-04 | 新河药品股份有限公司 | 抗滥用的苯丙胺前体药物 |
| JP2010512413A (ja) * | 2006-12-11 | 2010-04-22 | ケムファーム・インコーポレーテッド | アンフェタミンの非標準アミノ酸結合体およびそれらの製造方法および使用方法 |
| GB201002612D0 (en) * | 2010-02-16 | 2010-03-31 | Jagotec Ag | Improvements in or relating to organic compounds |
| CA2843390A1 (fr) * | 2011-07-29 | 2013-02-07 | Kempharm, Inc. | Promedicaments de l'homoarginine et/ou conjugues d'amphetamines et d'autres stimulants et leurs procedes de fabrication et d'utilisation |
| WO2014144115A1 (fr) * | 2013-03-15 | 2014-09-18 | Shire Llc | Polythérapie à doses prédéterminées pour la schizophrénie |
| WO2016102530A1 (fr) * | 2014-12-22 | 2016-06-30 | Bergen Teknologioverføring As | Dérivé d'acide phosphorique cyclique pour le traitement du syndrome de fatigue chronique |
-
2018
- 2018-04-10 JP JP2020506299A patent/JP2020516694A/ja active Pending
- 2018-04-10 US US16/603,936 patent/US20200155687A1/en not_active Abandoned
- 2018-04-10 CA CA3059781A patent/CA3059781A1/fr not_active Abandoned
- 2018-04-10 CN CN201880037925.XA patent/CN111107878A/zh active Pending
- 2018-04-10 EP EP18784661.3A patent/EP3618877A4/fr not_active Withdrawn
- 2018-04-10 MA MA050120A patent/MA50120A/fr unknown
- 2018-04-10 WO PCT/US2018/026973 patent/WO2018191311A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA3059781A1 (fr) | 2018-10-18 |
| CN111107878A (zh) | 2020-05-05 |
| US20200155687A1 (en) | 2020-05-21 |
| JP2020516694A (ja) | 2020-06-11 |
| EP3618877A4 (fr) | 2021-01-13 |
| WO2018191311A1 (fr) | 2018-10-18 |
| EP3618877A1 (fr) | 2020-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271046A (en) | Compounds for treating huntington's disease | |
| MA45192A (fr) | Traitement d'association | |
| EP3344274A4 (fr) | Méthodes et compositions pour le traitement d'états pathologiques associés à des réponses inflammatoires anormales | |
| ME03070B (fr) | Méthodes pour le traitement d'infections virales à filoviridae | |
| IL265528A (en) | aav therapy for Huntington's disease | |
| MA46954A (fr) | Méthodes de traitement d'états inflammatoires | |
| EP3370721A4 (fr) | Traitement de l'ostéoarthrite | |
| EP3668500A4 (fr) | Méthodes de traitement de l'arthrose à l'aide d'un gel de cannabidiol transdermique | |
| MA44083A (fr) | Composés de biarylmonobactame pour le traitement d'infections bactériennes | |
| EP3340971A4 (fr) | Méthodes de traitement de syndrome de lennox-gastaut à l'aide de fenfluramine | |
| EP3291815A4 (fr) | Méthodes de traitement d'une maladie neurodégénérative | |
| MA53329A (fr) | Méthodes de traitement de l'épilepsie | |
| EP3630102A4 (fr) | Formulations pour le traitement d'un trouble de stress post-traumatique | |
| EP3432891A4 (fr) | Méthodes de traitement et de prévention d'une infection à c. difficile | |
| EP3362065A4 (fr) | Polythérapie pour le traitement de malignités | |
| EP3285776A4 (fr) | Méthodes de traitement d'infections bactériennes | |
| EP3386520A4 (fr) | Méthodes de traitement d'une maladie ou d'un trouble oculaire | |
| EP3625971A4 (fr) | Traitement d'audio spatial | |
| EP3503904A4 (fr) | Traitement par ascaroside de l'oesophagite à éosinophiles | |
| EP3419622A4 (fr) | Traitement d'une maladie neurodégénérative de l'oeil à l'aide de pridopidine | |
| EP3766497A4 (fr) | Médicament pour le traitement de la toux | |
| SI3720433T1 (sl) | Bis-holin tetratiomolibdat za zdravljenje Wilsonove bolezni | |
| EP3454793A4 (fr) | Bobines de traitement d'anévrisme | |
| EP3393468A4 (fr) | Méthodes pour le traitement d'une maladie immunodéficiente | |
| HUE059387T2 (hu) | Parkinson-kór kezelése |